AIM
ONCY

Axiom Investment Management’s Oncolytics Biotech ONCY Stock Holding History

Axiom Investment Management’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$127 Buy
+150
New +$149 ﹤0.01% 379
2022
Q4 		– Sell
-150
Closed – – 317
2022
Q3 		$0 Buy
+150
New +$184 ﹤0.01% 448

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFP
Sandbox Financial Partners Bethesda, Maryland $356M AUM 19.83% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Axiom Investment Management's ONCY Position: Q1 2026 in Review

Axiom Investment Management opened a new position in Oncolytics Biotech (ONCY) in Q1 2026: 150 shares worth $127. The stake represents ﹤0.01% of the portfolio and ranks #379 among its holdings. This is a return to the name: Axiom Investment Management previously reported a position in ONCY as recently as Q3 2022.

Axiom Investment Management first reported a position in ONCY in Q3 2022 and has held it in 2 quarters since. 59 funds tracked by Wall St. Rank hold ONCY as of Q1 2026.

  • Axiom Investment Management held 150 shares of Oncolytics Biotech worth $127 as of Q1 2026.
  • Oncolytics Biotech was a new Axiom Investment Management position in Q1 2026.
  • Oncolytics Biotech made up ﹤0.01% of Axiom Investment Management's portfolio in Q1 2026, its #379 holding.
  • Axiom Investment Management first reported a position in Oncolytics Biotech in Q3 2022 and has held it in 2 quarters since.
  • 59 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2026.

Based on Axiom Investment Management's 13F filing for Q1 2026, filed 26 May 2026.